These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3874558)

  • 21. Corticotropin-releasing factor-like peptides increase cytosolic [Ca2+] in human epidermoid A-431 cells.
    Kiang JG
    Eur J Pharmacol; 1997 Jun; 329(2-3):237-44. PubMed ID: 9226418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of gastric acid secretion by brain peptides in the dog. Role of the autonomic nervous system and gastrin.
    Lenz HJ; Klapdor R; Hester SE; Webb VJ; Galyean RF; Rivier JE; Brown MR
    Gastroenterology; 1986 Oct; 91(4):905-12. PubMed ID: 2943629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sauvagine, urotensin I and CRF on food intake in rats.
    Negri L; Noviello L; Noviello V
    Peptides; 1985; 6 Suppl 3():53-7. PubMed ID: 3879535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo ACTH-releasing activity of ovine CRF, sauvagine and urotensin I.
    Rivier C; Rivier J; Lederis K; Vale W
    Regul Pept; 1983 Jan; 5(2):139-43. PubMed ID: 6298906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urotensin I, a CRF-like neuropeptide, stimulates acth release from the teleost pituitary.
    Fryer J; Lederis K; Rivier J
    Endocrinology; 1983 Dec; 113(6):2308-10. PubMed ID: 6315348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomic and cardiovascular effects of corticotropin-releasing factor in the spontaneously hypertensive rat.
    Brown MR; Hauger R; Fisher LA
    Brain Res; 1988 Feb; 441(1-2):33-40. PubMed ID: 2834002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the thermogenic effects of CRF, sauvagine and urotensin I in the rat.
    Le Feuvre RA; Rothwell NJ; White A
    Horm Metab Res; 1989 Sep; 21(9):525-6. PubMed ID: 2583676
    [No Abstract]   [Full Text] [Related]  

  • 28. Isolation, analysis of structure, synthesis, and biological actions of urotensin I neuropeptides.
    Lederis K; Letter A; McMaster D; Ichikawa T; MacCannell KL; Kobayashi Y; Rivier J; Rivier C; Vale W; Fryer J
    Can J Biochem Cell Biol; 1983 Jul; 61(7):602-14. PubMed ID: 6313156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pressor, tachycardic and behavioral excitatory responses in conscious rats following ICV administration of ACTH and CRF are blocked by naloxone pretreatment.
    Saunders WS; Thornhill JA
    Peptides; 1986; 7(4):597-601. PubMed ID: 3020526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional hemodynamic responses to central administration of corticotropin-releasing factor (CRF).
    Grosskreutz CL; Brody MJ
    Brain Res; 1988 Mar; 442(2):363-7. PubMed ID: 3259447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated vasoconstrictor responses by a vasodilator peptide, urotensin I: comparison with nifedipine.
    Bolt GR; Itoh H; Lederis K; MacCannell KL
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1147-54. PubMed ID: 2574741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of naloxone on the cardiovascular and respiratory effects of centrally administered corticotrophin releasing factor in conscious rabbits.
    May CN; Whitehead CJ; Mathias CJ
    Br J Pharmacol; 1991 Jul; 103(3):1776-80. PubMed ID: 1933140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the behavioral effects of CRF, sauvagine and urotensin I.
    Britton DR; Hoffman DK; Lederis K; Rivier J
    Brain Res; 1984 Jun; 304(2):201-5. PubMed ID: 6611193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies of the role of endothelium-dependent nitric oxide release in the sustained vasodilator effects of corticotrophin releasing factor and sauvagine.
    Barker DM; Corder R
    Br J Pharmacol; 1999 Jan; 126(1):317-25. PubMed ID: 10051151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fish neuropeptide urotensin I: its physiology and pharmacology.
    Lederis K; Fryer JN; Yulis CR
    Peptides; 1985; 6 Suppl 3():353-61. PubMed ID: 3008124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of corticotropin-releasing factor-stimulated adenylate cyclase activity in rat retina.
    Olianas MC; Onali P
    J Neurochem; 1990 Jun; 54(6):1967-71. PubMed ID: 2159980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats.
    Diamant M; Kashtanov SI; Fodor M; de Wied D
    Neuroendocrinology; 1992 Nov; 56(5):750-60. PubMed ID: 1488107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
    Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
    J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The suppression effects of feeding and mechanisms in CRF system of animals.
    Qi J; Zhang X; Li Y; Xu S; Wang M; Chen H; Tang N; Wang S; Wang B; Chen D; Zhou B; Li Z
    Gene; 2020 Apr; 733():144363. PubMed ID: 31935510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular responses to exercise in the rat: role of corticotropin-releasing factor.
    Kregel KC; Overton JM; Seals DR; Tipton CM; Fisher LA
    J Appl Physiol (1985); 1990 Feb; 68(2):561-7. PubMed ID: 2318769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.